|Day Low/High||42.05 / 42.42|
|52 Wk Low/High||36.00 / 46.38|
MYOPLEX® KETOGENIC DELIVERS THE RIGHT AMOUNT OF NUTRIENTS NEEDED TO SUPPORT A KETOGENIC REGIMEN AND HELP ATHLETES ACHIEVE THEIR BODY AND PERFORMANCE GOALS
The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.
U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.
Abbott Laboratories (ABT) will sell its eye surgery unit to Johnson & Johnson (JNJ) for $4.325 billion in cash.
- Abbott continues to shape its portfolio for long-term growth
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?
Cramer is sticking with International Paper and likes Advanced Micro Devices.
This is not the time to sell in a panic, Cramer says.
Abbott Labs shares have been all over the place in the last year as the company makes deals. Investors are wondering if they should hold on.
Abbott Laboratories (ABT) and Alere (ALR) agreed today to work with a mediator to solve issues in their ongoing merger dispute.
- Achieves top industry scores in all three categories of economic, environmental and social performance, and more than doubles the overall average industry score
The cardiac device maker has filed a lawsuit against the Muddy Waters, claiming the short-seller intentionally disseminated false and misleading information.
Zoetis' valuation doesn't reflect opportunities from innovation, operational improvements, and capital allocation, according to one analyst.
Potential targets of the medical device and diagnostics giant might request stricter parameters when structuring a deal, company followers say.
Alere claims that Abbott is slow-rolling the antitrust process on the companies' merger in an effort to kill the deal.
The provider of point-of-care testing has filed a suit in Delaware Chancery Court against Abbott in an effort to complete their pending deal. Meanwhile, St. Jude, gets a griping short-seller.
Alere (ALR) sued Abbott (ABT) on Friday saying the medical device company failed to get U.S. antitrust approval for its merger.
Abbott Laboratories (ABT) stock was increasing Thursday afternoon as Muddy Waters attempts to break up the company's proposed acquisition of St. Jude (STJ).
Here are Wednesday's top research calls, including upgrades for Abbott Labs and NetApp, and downgrades for Garmin and Nordsom.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, AXLL, BOKF, FLY, KCAP, RWC Downgrades: BBRG, CCOI, DL, EMG, FLO, HWBK, IIJI, INOD, MTH, NOA, SMCI, SNY, TGNA Initiations: BUFF, GI, NSA Read on to get TheStreet Quant Ratings' detailed report:
Abbott Laboratories (ABT) has great growth prospects and has paid increasing dividends for more than 40 years. Here's why this Dividend Aristocrat should be in your investment portfolio.
Abbott Laboratories (ABT) said Alere (ALR) hasn't disclosed key information, making the company question whether its proposed $5.8 billion deal will close.
Insiders at these companies have been scooping up shares of their own stock lately.